Akouos, Inc. financial data

Industry
Pharmaceutical Preparations
Location
645 Summer Street, Suite 200, Boston, MA
State of incorporation
DE
Fiscal year end
November 30
Latest financial report
10-Q - Q3 2022 - Nov 14, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.36K % -48.3%
Debt-to-equity 22.3 % +97.2%
Return On Equity -45.1 % -73%
Return On Assets -36.9 % -57.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.9M shares +7.11%
Common Stock, Shares, Outstanding 36.9M shares +7.07%
Common Stock, Value, Issued 4K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 36.9M shares +7.17%
Weighted Average Number of Shares Outstanding, Diluted 36.9M shares +7.17%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 67.5M USD +26.2%
General and Administrative Expense 25.8M USD +22.6%
Operating Income (Loss) -93.2M USD -25.2%
Nonoperating Income (Expense) 623K USD +235%
Net Income (Loss) Attributable to Parent -92.6M USD -24.7%
Earnings Per Share, Basic -2.62 USD/shares +19.4%
Earnings Per Share, Diluted -2.62 USD/shares +19.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 75.4M USD -34.2%
Marketable Securities, Current 93.9M USD -30.5%
Assets, Current 174M USD -31.4%
Operating Lease, Right-of-Use Asset 19.6M USD -5.17%
Other Assets, Noncurrent 28K USD -92.3%
Assets 226M USD -24.2%
Accounts Payable, Current 562K USD -47.3%
Employee-related Liabilities, Current 3.35M USD +45.4%
Liabilities, Current 10.1M USD -23.1%
Operating Lease, Liability, Noncurrent 34.6M USD +23%
Liabilities 44.7M USD +8.35%
Accumulated Other Comprehensive Income (Loss), Net of Tax -742K USD -5608%
Retained Earnings (Accumulated Deficit) -236M USD -64.5%
Stockholders' Equity Attributable to Parent 181M USD -29.4%
Liabilities and Equity 226M USD -24.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.1M USD -26%
Net Cash Provided by (Used in) Financing Activities 220K USD +20.2%
Net Cash Provided by (Used in) Investing Activities -47.7M USD -173%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 36.9M shares +7.07%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 77.9M USD -33.5%
Operating Lease, Liability 35.4M USD +23%
Payments to Acquire Property, Plant, and Equipment 2.79M USD -32%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -93.3M USD -25.6%
Lessee, Operating Lease, Liability, to be Paid 56.8M USD +6.27%
Operating Lease, Liability, Current 785K USD +23.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.61M USD +11.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.25M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 21.5M USD -13.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.79M USD +3.12%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.96M USD +3.01%
Operating Lease, Payments 807K USD
Additional Paid in Capital 418M USD +4.49%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3.09M USD +39.2%
Share-based Payment Arrangement, Expense 10.4M USD +18.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%